Atlas market file · Equity · United States
Adagio Medical Holdings, Inc.ADGM
- Last close
- 0.732
- Change
- -0.95%
- 96-bar range
- 0.363 – 1.69
- As of
- 6 Aug 2026
Adagio Medical Holdings, Inc. is a surgical & medical instruments & apparatus issuer listed as ADGM on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
ADGM
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-85.92% over the window).
Source rail: Yahoo Finance chart API (ADGM). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for ADGM. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
ADGM public profile
Surgical & medical instruments & apparatus issuer. Adagio Medical Holdings, Inc. is connected to current market context, cited company sources and its retained research file.
Adagio Medical Holdings, Inc. trades as ADGM on NASDAQ. Adagio Medical Holdings, Inc. (ADGM) has a latest verified close of 0.732, down 0.95%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files ADGM under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Adagio Medical Holdings, Inc. today
Adagio Medical Holdings (ADGM) kicked off 2026 with a stark financial reality: zero revenue, a $7M net loss, and $4.1M in negative operating cash flow for the quarter ending March 31, per its 10-Q filing. The medical device firm, touting its vCLAS Ventricular Ablation System as a breakthrough, spent $2.7M on R&D despite having just $12.9M in cash and $33.6M in liabilities.
Adagio’s core business revolves around cardiac ablation technology, specifically the vCLAS system, which targets ventricular arrhythmias. The company submitted a Premarket Approval (PMA) application to the FDA in May 2026, a critical step toward commercialization. However, without approval, ADGM remains a cash-burning entity reliant on investor faith and balance sheet gymnastics to stay solvent.
Recent filings highlight governance shifts: an 8-K on June 16 revealed executive compensation changes, while another on May 21 detailed a Facilities and Services Agreement with Fjord Ventures. The company’s inventory stood at $1.6M, down slightly from Q4, and its diluted EPS sunk to -$0.31. With 22.2M shares outstanding, dilution risks loom if equity issuances continue.
Chart-wise, ADGM’s liquidity remains untested in this analysis, as no price data was supplied. The lack of revenue and pending FDA decision create a binary catalyst: approval could spark a re-rating, while rejection risks accelerating the cash burn crisis.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
ADGM technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on ADGM
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep ADGM research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
ADGM FAQ
What is Adagio Medical Holdings, Inc. (ADGM)?Adagio Medical Holdings, Inc. (ADGM) has a latest verified close of 0.732, down 0.95%, dated 6 Aug 2026. Use this page to check the price chart, company context,...
Adagio Medical Holdings, Inc. (ADGM) has a latest verified close of 0.732, down 0.95%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for ADGM?Adagio Medical Holdings, Inc. (ADGM) has a latest verified close of 0.732, down 0.95%, dated 6 Aug 2026. It brings the latest available chart, company context, cited...
Adagio Medical Holdings, Inc. (ADGM) has a latest verified close of 0.732, down 0.95%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files ADGM under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the ADGM page updated?The ADGM public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The ADGM public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for ADGM?The ADGM file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:ADGM. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The ADGM file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:ADGM. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on ADGM?Yes. The workstation can open ADGM, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open ADGM, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this ADGM page investment advice?No. The ADGM page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The ADGM page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →